Results of the SHINE Trial find 4 months of antituberculosis treatment was non-inferior to 6 months for children with non-severe TB (published today).
Fourth year medical student at Stellenbosch, Inati Mcapazeli, examines x-rays at the Brooklyn Chest Hospital, Cape Town.
The SHINE trial is a phase 3 randomised open-label trial comparing four versus six months of treatment with rifampicin, isoniazid, pyrazinamide plus or minus ethambutol in children with smear-negative, non-severe TB. It was conducted in five study sites in South Africa, Uganda, Zambia and India.
The outcomes published by Turkova et al. today demonstrate that four months of antituberculosis treatment was noninferior to six months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis.
This important finding will be incorporated in the new WHO Child TB guidelines and handbook that will be released in a fortnight (on World TB Day March 24th).
We would like to applaud TB-CRE Chief Investigator Prof Steve Graham for his contribution to the SHINE team, and as the chair of the WHO Guideline Development Group.
Congratulations on this outstanding outcome Steve!
Prof Steve Graham
Read the paper here.
